PD-1 vs PD-L1: Why Small Translation Errors Matter in Cancer Records
- MedBridgeNZ
- Aug 2
- 13 min read
In an oncology record, the difference between PD-1 and PD-L1 may appear to be only two characters. Clinically, however, the terms do not describe the same protein, the same drug target, or the same type of medical information. PD-1 is an immune checkpoint receptor found on immune cells, including T cells. PD-L1 is one of the proteins that can bind to PD-1. Some medicines block PD-1, while others block PD-L1.
The distinction becomes particularly important when cancer records move between hospitals, countries, and languages. A translated file may need to distinguish among:
a medicine targeting PD-1;
a medicine targeting PD-L1;
a PD-L1 pathology test;
a PD-L1 expression score;
a treatment already administered;
a treatment only considered or discussed.
A small wording inconsistency does not establish that a medical error occurred. It can, however, make the treatment history unclear or change how a proposed regimen is understood.
Key Takeaways
PD-1 and PD-L1 belong to the same immune checkpoint pathway, but they are not interchangeable terms.
A PD-L1 biomarker result does not mean that the patient received an anti-PD-L1 medicine.
Generic drug names should remain visible in translated oncology records whenever available.
“Received,” “planned,” “considered,” and “available” describe different treatment statuses.
When source documents conflict, the discrepancy should be preserved and routed for clarification rather than silently corrected.
Quick Answer
A PD-1 vs PD-L1 translation error can change the stated drug target, confuse a biomarker result with a treatment, or make it unclear which medicine a patient previously received.
A structured translation process should:
preserve the exact generic drug name;
separate treatment history from proposed treatment;
distinguish PD-L1 testing from PD-L1-targeted therapy;
retain the assay name, scoring method, and numerical result;
document inconsistent wording across source records;
route unresolved terminology to the originating physician or institution.
A translator or medical concierge should preserve the record and its uncertainties—not independently decide which clinical term was intended.
PD-1: an immune checkpoint receptor and drug target.PD-L1: a ligand and a different drug target.PD-L1 test: a biomarker result, not a treatment record.
PD-1 vs PD-L1: Why Are They Not Interchangeable?
PD-1 and PD-L1 are biologically connected, but they refer to different proteins. Some immune checkpoint medicines bind to PD-1. Others bind to PD-L1. They may all be described broadly as checkpoint inhibitors, but the broad category should not replace the precise drug name or molecular target when that information is available. For example:
nivolumab is an anti-PD-1 antibody;
atezolizumab is an anti-PD-L1 antibody;
a PD-L1 pathology result describes biomarker expression rather than administration of either medicine.
These statements therefore have different meanings:
The patient received anti-PD-1 therapy.
The patient received anti-PD-L1 therapy.
The tumour showed PD-L1 expression.
The first two describe different treatment targets. The third describes a test result. When a translated summary blurs these distinctions, the receiving oncologist may need to return to the original medication, infusion, or pathology records before relying on it.
PD-1, PD-L1, and PD-L1 Testing: Three Different Records
Entity | What It Is | Typical Use Case |
PD-1 | An immune checkpoint receptor and treatment target | Describing medicines such as nivolumab |
PD-L1 | A ligand that binds to PD-1 and is also a treatment target | Describing medicines such as atezolizumab |
PD-L1 test result | A tissue-based biomarker finding reported through a specified assay and scoring method | Supporting disease- and medicine-specific discussions with the oncology team |
These entities belong to the same biological pathway, but they represent different categories of medical information.
What Does Anti-PD-1 Mean?
Definition: An anti-PD-1 antibody is a medicine that binds to the PD-1 receptor.
Function: It blocks checkpoint signalling through PD-1.
Typical Use Case: The term may appear in an oncology treatment history, infusion record, consultation note, or proposed treatment plan.
Why This Matters: When the exact medicine is known, “nivolumab, an anti-PD-1 antibody” is more traceable than a general phrase such as “PD treatment.”
What Does Anti-PD-L1 Mean?
Definition: An anti-PD-L1 antibody is a medicine that binds to PD-L1 rather than PD-1.
Function: It interferes with the interaction between PD-L1 and PD-1.
Typical Use Case: The term may appear when documenting a medicine such as atezolizumab.
Why This Matters: An anti-PD-L1 medicine should not automatically be recorded as anti-PD-1 merely because both act on the same checkpoint pathway.
What Does a PD-L1 Test Measure?
Definition: A PD-L1 test examines PD-L1 expression in a tissue sample through a defined pathology assay.
Function: It provides biomarker information that may be considered within a disease-, assay-, and medicine-specific framework.
Typical Use Case: The pathology report may contain an assay name, antibody clone, scoring method, numerical result, and laboratory interpretation.
Why This Matters: A PD-L1 result does not document that checkpoint immunotherapy was prescribed or administered.
How Can a Small Translation Error Change the Meaning?
It Can Change the Recorded Treatment History
A reliable treatment record normally begins with the generic medicine name.
Compare:
The patient received nivolumab, an anti-PD-1 antibody.
with:
The patient received PD-L1 treatment.
The second sentence changes the stated treatment target and removes the precise medicine name another oncologist may need when examining treatment sequence, previous response, or possible adverse effects.
It Can Change a Proposed Regimen
An informal summary may describe a possible combination as containing an anti-PD-1 antibody, while a later report refers to an anti-PD-L1 antibody. The difference could reflect:
an inaccurate summary;
a translation inconsistency;
shorthand used in correspondence;
a genuine change in the proposed medicine;
a later clarification from the specialist.
Unless the exact medicine is named, the documents may not show which explanation is correct. The translator should not select whichever term appears more medically likely. Both versions should remain visible until the originating physician or institution clarifies the intended medicine.
It Can Confuse a Biomarker With a Medicine
The phrase: PD-L1 TPS 0%
describes a biomarker result.
The phrase: The patient received an anti-PD-L1 antibody
describes treatment.
Combining these ideas into wording such as “the patient had negative PD-L1 treatment” would create an inaccurate record.
It Can Alter Treatment Status
Clinical verbs can be as important as medicine names.
These statements describe different situations:
the patient received nivolumab;
nivolumab was prescribed;
nivolumab was planned;
the specialist suggested discussing nivolumab;
the hospital confirmed availability of nivolumab.
A treatment that was discussed should not appear in a translated history as though it was administered.
It Can Complicate Adverse-Effect Discussions
Immune checkpoint medicines can be associated with inflammatory adverse effects involving different organs. When physicians consider whether a new symptom may be treatment-related, the exact medicine, combination partner, treatment date, and number of doses may be relevant. A record stating only “immunotherapy” may not provide enough information. A record naming the wrong checkpoint target can create additional uncertainty.
What Information Should Be Preserved in the Translation?
1. The Exact Generic Drug Name
The generic name should remain visible whenever it appears in the source record.
Examples include:
nivolumab;
pembrolizumab;
atezolizumab;
durvalumab;
ipilimumab;
temozolomide.
Brand names may be added where useful, but they should not replace the generic name.
2. Whether the Treatment Was Received or Only Discussed
The translated document should preserve whether a medicine was:
administered;
prescribed;
planned;
considered;
suggested for discussion;
confirmed as institutionally available.
These statuses should not be merged.
3. The Combination Partners
“Checkpoint immunotherapy” may describe a single medicine or a combination.
Where documented, the translated treatment history should retain:
each medicine’s generic name;
treatment dates;
recorded cycles or doses;
the stated reason for stopping;
the recorded response;
adverse effects documented by the treating team.
4. Whether PD-L1 Refers to Testing or Treatment
Context usually helps distinguish the two. Terms that commonly indicate biomarker testing include:
immunohistochemistry or IHC;
Tumour Proportion Score or TPS;
Combined Positive Score or CPS;
staining;
tumour cells;
immune cells;
assay;
antibody clone.
Terms that commonly indicate treatment include:
administered;
infusion;
dose;
cycle;
regimen;
generic medicine name.
The translator should preserve the source wording rather than independently determine whether the result supports treatment eligibility.
5. The Original Scoring Method
TPS and CPS are different PD-L1 scoring systems. They should not be treated as equivalent or converted by a translator. A translated pathology entry should retain:
the scoring method;
the numerical result;
the original positive or negative wording;
the assay name or antibody clone, when stated;
the laboratory’s interpretive comment.
6. Conflicts Between Source Documents
A medication list, oncologist’s letter, patient-completed form, pathology report, and email summary may not use identical terminology. Where a primary source clearly names the medicine, that source can be identified in the compiled record. Where the conflict remains unresolved, it should be presented as a clarification question.
Which Wording Is More Traceable?
Source Information | Ambiguous Wording | More Traceable Record Format |
Nivolumab was administered | Patient received PD therapy | Nivolumab, an anti-PD-1 antibody, was administered |
Atezolizumab was proposed | PD-1 treatment was proposed | Atezolizumab, an anti-PD-L1 antibody, was proposed |
PD-L1 TPS was reported | Patient had a PD-L1 treatment result | Tumour PD-L1 expression was reported using TPS |
A checkpoint inhibitor was discussed but not named | PD-1 medicine recommended | An unnamed checkpoint inhibitor was discussed; the exact medicine requires clarification |
One record says PD-1 and another says PD-L1 | One term is silently substituted | Both source terms are retained pending confirmation |
The objective is not to make the translated record sound more polished. It is to preserve what is documented, distinguish it from what remains uncertain, and prevent an unresolved term from becoming an assumed clinical fact.
In Chinese-English oncology records, the following distinctions should also remain clear:
抗PD-1抗体 — anti-PD-1 antibody;
抗PD-L1抗体 — anti-PD-L1 antibody;
PD-L1表达 — PD-L1 expression;
PD-L1检测 — PD-L1 testing.
A broad phrase such as “PD immunotherapy” should not replace the exact medicine or test information when more precise documentation is available. International patients can also review how MedBridgeNZ coordinates bilingual medical record preparation and cross-border communication.
Clinical Case Study
The following administrative case example has been de-identified. Nonessential clinical, geographic, and timeline details have been generalised or omitted to reduce re-identification risk. It is presented solely to illustrate terminology control in cross-border medical records—not treatment selection, treatment effectiveness, or clinical outcome.
Patient Profile
An international patient with advanced melanoma had previously received combined CTLA-4 and PD-1 immunotherapy. The available treatment records consistently documented the previous checkpoint target as PD-1.
Initial Recommendation
A remote specialist consultation was coordinated so that the patient’s treatment history and supporting records could be considered before decisions were made about possible care in China. For this article, the relevant issue is not whether any proposed regimen was clinically appropriate. It is how the checkpoint component was described in different documents.
Why a Second Opinion Was Sought
The family requested another oncology perspective after previous treatment.
Specialist Review and Terminology Comparison
The available records documented an individual specialist consultation rather than a formal multidisciplinary tumour-board meeting. An earlier administrative summary described the checkpoint component of a possible combination as anti-PD-1. A later formal consultation report described the component as anti-PD-L1. The relevant passages did not name the specific checkpoint medicine. Based on the documents alone, it was not possible to determine whether:
the earlier summary contained an inaccurate term;
the later report contained an inaccurate term;
the proposed medicine had changed;
the later document reflected a subsequent clarification.
Selecting one term based only on general medical knowledge would have introduced an unsupported assumption.
Outcome
In this situation, a more traceable administrative approach would be to preserve both source versions and route the terminology question to the originating specialist before relying on the information for further coordination.
The available records do not document whether a subsequent clarification was completed. They also do not establish that the proposed medicine was started or that the terminology discrepancy affected the patient’s treatment.
This example illustrates a documented inconsistency in cross-border medical records. It does not establish that a medication error occurred.
Please note: Individual medical outcomes vary significantly depending on baseline health, prior treatments, and specific disease progression.
How Should Conflicting PD-1 and PD-L1 Wording Be Clarified?
Do Not Correct the Record Silently
A translator may know that a named medicine targets PD-1 or PD-L1. That knowledge can help expose a possible discrepancy, but it does not authorise the translator to rewrite an unnamed physician proposal. Silent correction removes evidence that the source records originally differed.
Return to the Generic Drug Name
The most useful clarification question is usually:
What is the exact generic name of the checkpoint inhibitor being discussed?
Once the medicine has been confirmed, its drug target can be documented accurately.
Ask Whether the Proposed Treatment Changed
When an informal summary and a formal report differ, the physician may have revised the intended regimen. Clarification should therefore address:
which medicine was intended;
whether the later document replaces the earlier wording;
whether the proposed combination changed.
Retain a Traceable Clarification Note
After confirmation, the translated record may state:
An earlier summary used “anti-PD-1.” The originating specialist subsequently confirmed that the intended medicine was [generic drug name], an anti-[PD-1/PD-L1] antibody.
This format preserves the document history while making the clarification visible.
Do Not Infer Treatment Eligibility
Confirming a medicine name does not determine whether the medicine is appropriate, available, or safe for the patient. Clinical eligibility remains subject to the treating physicians, current medical information, and the receiving institution’s requirements.
When Should PD-1 and PD-L1 Wording Be Rechecked?
A structured terminology check may be particularly relevant when the records contain:
previous PD-1, PD-L1, or CTLA-4 immunotherapy;
several generic and brand medicine names;
treatment summaries written from memory;
pathology reports containing PD-L1 scores;
documents translated between Chinese and English;
informal correspondence that differs from the formal report;
combination therapies that do not name every medicine;
records from several hospitals or healthcare systems.
Document clarification should not delay urgent local care. A patient with rapidly worsening symptoms or possible treatment complications should contact the local treating team. Overseas document preparation is not a substitute for emergency medical assessment.
Why Does the Exact Drug Name Matter When Side Effects Are Discussed?
Anti-PD-1 and anti-PD-L1 medicines can both be associated with immune-related adverse effects. Representative effects may include skin reactions and inflammation involving organs such as the:
bowel;
lungs;
liver;
thyroid;
adrenal or pituitary glands;
nervous system;
heart.
The actual risks depend on factors such as:
the exact medicine;
combination partners;
dose and treatment schedule;
previous therapies;
baseline health;
current symptoms;
organ function.
When physicians consider whether a symptom may be treatment-related, a vague entry such as “immunotherapy” may be insufficient. Patients should discuss the following with the prescribing oncologist:
the generic and brand name;
the treatment target;
the purpose of treatment;
the combination regimen;
required monitoring;
expected adverse effects;
symptoms requiring urgent medical attention;
whether previous checkpoint treatment affects the current plan.
MedBridgeNZ does not determine whether checkpoint immunotherapy is appropriate for an individual patient.
How MedBridgeNZ Coordinates Bilingual Oncology Records
Cross-border oncology information may appear across consultation forms, physician letters, pathology reports, genomic reports, medication lists, discharge summaries, and email correspondence. MedBridgeNZ can:
compile the available records into a structured case file;
format the documented treatment history chronologically;
translate relevant records between English and Chinese;
retain generic medicine names and original biomarker terminology;
compile conflicting source terms into a structured clarification list;
route clarification questions to the relevant physician or institution;
facilitate delivery of the translated consultation report to the patient.
MedBridgeNZ does not independently decide which medicine was intended, interpret PD-L1 treatment eligibility, or change a physician’s treatment proposal.
Frequently Asked Questions
Is nivolumab a PD-1 or PD-L1 medicine?
Nivolumab is an anti-PD-1 antibody. A translated treatment history should retain the generic name “nivolumab” and may describe it as targeting PD-1. It should not be relabelled as anti-PD-L1 therapy.
Is atezolizumab a PD-1 or PD-L1 medicine?
Atezolizumab is an anti-PD-L1 antibody. It targets PD-L1 rather than the PD-1 receptor.
The generic drug name should remain visible in the translated record.
Does a PD-L1 TPS result mean the patient received PD-L1 immunotherapy?
No. TPS is a pathology scoring method used to report PD-L1 expression in tumour tissue.
It is a biomarker result, not evidence that an anti-PD-L1 medicine was prescribed or administered.
Can a translator convert a PD-L1 TPS result into CPS?
No. TPS and CPS are different scoring methods.
A translator should preserve the scoring method and numerical result stated in the original pathology report. Clinical reinterpretation should be referred to the pathologist or treating oncologist.
Can anti-PD-1 and anti-PD-L1 be translated as the same treatment?
They may both be described broadly as immune checkpoint inhibitors affecting the PD-1–PD-L1 pathway. However, the specific terms are not interchangeable because the medicines bind to different molecular targets.
What documents can confirm which checkpoint inhibitor was administered?
Potentially useful records include:
oncology treatment summaries;
infusion-centre records;
pharmacy records;
medicine labels;
invoices containing generic drug names;
discharge summaries;
clinical-trial records;
letters from the prescribing oncologist.
A patient-written summary can provide context, but it should not automatically replace the original treatment record.
What should happen when one document says PD-1 and another says PD-L1?
Both versions should be preserved until the originating physician or institution confirms the exact medicine and whether the proposed treatment changed. The translator or coordinator should not silently select the term that appears more likely.
Understanding the Translation Pathway Before Cross-Border Review
Accurate oncology translation does not require the translator to make clinical decisions. It requires the translated record to distinguish documented facts, proposed treatments, biomarker findings, and unresolved questions. For checkpoint-immunotherapy records, the generic drug name should remain the central reference point. PD-1, PD-L1, and PD-L1 testing should be treated as related but separate entities.
1. Initial Case Intake
The patient submits the available physician letters, pathology reports, imaging reports, medication records, and treatment summaries. MedBridgeNZ can compile, format, and translate these materials into a structured bilingual case file. Unclear abbreviations and conflicting entries can be recorded as clarification questions rather than silently rewritten.
2. Specialist Matching and Consultation Setup
Based on the documented disease area and the purpose of the consultation, MedBridgeNZ can administratively match the case with an available specialist pathway and coordinate the consultation setup. Where PD-1, PD-L1, or a medicine name remains unclear, MedBridgeNZ can route a clarification question to the relevant physician or institution. Clinical interpretation remains the responsibility of the physician.
3. On-the-Ground Coordination
After the patient, specialist, and receiving institution confirm an in-person pathway, MedBridgeNZ can coordinate appointment scheduling, hospital-system navigation, bilingual accompaniment, local transportation, and accommodation arrangements. International patients whose oncology records contain inconsistent drug names, unclear PD-1 or PD-L1 terminology, or ambiguous biomarker wording may submit the original documents to MedBridgeNZ for:
document compilation;
structured formatting;
bilingual translation coordination;
administrative routing of unresolved terminology questions.
Clinical ambiguities are routed to the relevant physician or institution rather than interpreted independently by MedBridgeNZ. Patients may submit an initial inquiry through the MedBridgeNZ Contact Us page to learn about the available administrative intake and bilingual record-preparation process.
References
National Cancer Institute. Definition of PD-1. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pd-1
National Cancer Institute. Definition of PD-L1. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/pd-l1
National Cancer Institute. Definition of Nivolumab. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nivolumab
National Cancer Institute. Definition of Atezolizumab. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atezolizumab
U.S. Food and Drug Administration. PD-L1 IHC 22C3 pharmDx—Tumor Proportion Score and Combined Positive Score. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150013s016
National Cancer Institute. Immune Checkpoint Inhibitors. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors
Flores G, Abreu M, Barone CP, Bachur R, Lin H. Errors of Medical Interpretation and Their Potential Clinical Consequences: A Comparison of Professional Versus Ad Hoc Versus No Interpreters. https://pubmed.ncbi.nlm.nih.gov/22424655/
World Health Organization. Medication Safety in Transitions of Care. https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.9
MedBridgeNZ. Mucosal Melanoma Second Opinion After Immunotherapy Failure: A Remote Case Study. https://www.medbridgenz.com/case-studies/mucosal-melanoma-remote-second-opinion
Disclaimer: MedBridgeNZ acts strictly as an international medical concierge and logistics coordinator. We do not provide direct medical treatment, diagnosis, or clinical advice. This content is for informational purposes only and does not constitute medical guidance. Always consult your primary physician or treating oncologist before pursuing cross-border treatment options.
